ReviewInternational journal of endocrinology and metabolism2026
Cardiovascular Disease Mortality Events and Predictors in the Tehran Lipid and Glucose Study: A 20-Year Cohort Review .
Review in International journal of endocrinology and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context: We summarized findings from the Tehran Lipid and Glucose Study (TLGS) on cardiovascular disease (CVD) mortality and its predictors over nearly two decades. Evidence Acquisition: A review was undertaken to retrieve TLGS publications related to CVD mortality and predictors from the January 1999 to August 5, 2025. Results: Across TLGS studies, the crude incidence rate of CVD mortality ranged from 1.7 to 4.1 per 1000 person-years in adults aged ≥ 30 years, with higher rates observed among men than women. CVD mortality was associated with traditional risk factors such as diabetes, hypertension, metabolic syndrome (MetS), and dyslipidemia, as well as emerging markers including continuous MetS severity score, anthropometric indices, dynamic weight change, kidney function decline, resting pulse rate, and adherence to cardiovascular health metric. Evidence also highlighted differential associations by age, sex, and diabetes status. Subgroup analyses indicated that elderly participants and those with metabolic abnormalities had higher CVD and sudden cardiac death (SCD) risks. Conclusions: Tehran Lipid and Glucose Study studies have provided comprehensive insights into the epidemiology and predictors of CVD mortality in the Iranian population, emphasizing both traditional and emerging risk factors. These findings can inform tailored prevention and intervention strategies, though further research incorporating dynamic risk models, omics data, and sex-specific analyses is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.